U.S. markets closed

MacroGenics, Inc. (MGNX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
12.71-0.19 (-1.47%)
At close: 04:00PM EST
12.71 0.00 (0.00%)
After hours: 04:31PM EST

MacroGenics, Inc.

9704 Medical Center Drive
Rockville, MD 20850
United States
301 251 5172

Full Time Employees370

Key Executives

NameTitlePayExercisedYear Born
Dr. Scott Koenig M.D., Ph.D.CEO, Pres & Director1.05M783k1952
Mr. James KarrelsSr. VP, CFO & Corp. Sec.613.84k139.42k1967
Dr. Ezio BonviniSr. VP of Research & Chief Scientific Officer658.21kN/A1954
Mr. Eric Blasius RisserSr. VP of Bus. Devel. & Portfolio Management and Chief Bus. Officer609.91k523.31k1973
Dr. Stephen L. EckSr. VP of Clinical Devel. & Chief Medical Officer577.62kN/A1955
Dr. Christopher Shayne James M.D.VP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Mr. Jeffrey Stuart PetersVP & Gen. CounselN/AN/A1971
Dr. Thomas M. SpitznagelSr. VP of BioPharmaceutical Devel. & ManufacturingN/AN/A1967
Ms. Lynn CilinskiVP, Controller & TreasurerN/AN/A1958
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics to treat cancer in the United States. The company's approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase II/III clinical trial for the treatment of breast and gastroesophageal cancers. The company is also developing Flotetuzumab, a DART molecule that recognizes CD123 and CD3 for treating acute myeloid leukemia; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; Enoblituzumab, a monoclonal antibody that targets B7-H3; and Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3. In addition, it is developing MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; MGD019, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company's non-immuno-oncology clinical product candidates include MGD014, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; Janssen Biotech, Inc.; and Alligator Bioscience AB (publ). The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

Corporate Governance

MacroGenics, Inc.’s ISS Governance QualityScore as of September 26, 2021 is 6. The pillar scores are Audit: 4; Board: 3; Shareholder Rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.